<a href="https://laohu8.com/S/PMVP">PMV Pharmaceuticals</a> reports third quarter loss as cash reserves fall to $129.3 million
PMV Pharmaceuticals Inc. reported a net loss of $21.1 million for the third quarter ended September 30, 2025, compared to a net loss of $19.2 million in the same period in 2024. Research and development expenses increased to $18.2 million from $16.9 million, primarily due to higher contractual research organization costs related to the advancement of the rezatapopt program. General and administrative expenses decreased to $4.3 million from $4.9 million, mainly due to reduced stock-based compensation and lower facility and operational expenses. As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $129.3 million, expected to provide a cash runway through the first quarter of 2027. Business developments included updated clinical results from the Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt, with a 46% overall response rate observed in the ovarian cancer cohort. PMV Pharmaceuticals plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-276000), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.